The company’s stock surges 236% on first data with its new EGFR project, so where’s the catch?
Lilly follows others into the oral autoimmune space, not long after its leader questioned the future of small molecules.
China’s Dizal, an unexpected targeted therapy star of Asco 2021, is back with even more impressive data.
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.
SRP-9001 heads for its month of regulatory probing, as vaccines from GSK and Pfizer, and Genmab and Abbvie’s bispecific, await FDA approval decisions.
Ulcerative colitis data promise the efficacy and safety of Entyvio, but in a pill.
The Japanese developer is an active name in the autoimmune condition, and with its first deal over ADCs it joins others with antibody approaches.